Abstract
PKC-θ is a serine/threonine specific protein kinase and its activation depends upon the concentration of diacylglycerol (DAG) and phospholipids (phosphatidylserine). PKC-θ phosphorylates a variety of proteins that are known to be involved in the diverse cellular signaling pathways. It is predominantly expressed in the T-cells and localized in the center of immunological synapse upon T-cell receptor (TCR) and CD28 signaling. Activation of PKC-θ leads to the activation of various transcription factors in the nuclei of T-cells, e.g. NF-κB, NFAT, c-Jun, c-Fos and AP-1 that further control the proliferation and differentiation of T-cells. Defective T-cell activation in turn leads to the aberrant expression of apoptosis related proteins that cause the poor T-cell survival. Researchers have found that T-cells deficient in PKC-θ exhibit reduced interleukin-2 (IL-2) production. Apart from this role on IL-2 expression, it also plays crucial roles in the proliferation, differentiation and survival of the T-cells, which make it an attractive therapeutic target for a variety of immunological and T-cell mediated diseases. Hence, new molecules capable of modulating the expression or biological activity of PKC-θ are being developed and tested for their potential as novel therapy for several T-cells mediated disease conditions such as multiple sclerosis, rheumatoid arthritis, asthma, inflammatory bowel disease and organ transplantation, etc. In the present review, we tried to integrate the recent discoveries on PKC-θ including its pharmacology and therapeutic potential, along with brief update on its inhibitor molecules.
Keywords: Autoimmune diseases, diacylglycerol (DAG), NF-κB, protein kinase C theta (PKC-θ), rheumatoid arthritis (RA), phospholipids, T-cells, CD28 signaling, interleukin-2, inflammatory bowel disease.
Current Pharmaceutical Design
Title:Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Volume: 18 Issue: 30
Author(s): Sukhvir Chand, Nisha Mehta, Malkeet Singh Bahia, Anshuman Dixit and Om Silakari
Affiliation:
Keywords: Autoimmune diseases, diacylglycerol (DAG), NF-κB, protein kinase C theta (PKC-θ), rheumatoid arthritis (RA), phospholipids, T-cells, CD28 signaling, interleukin-2, inflammatory bowel disease.
Abstract: PKC-θ is a serine/threonine specific protein kinase and its activation depends upon the concentration of diacylglycerol (DAG) and phospholipids (phosphatidylserine). PKC-θ phosphorylates a variety of proteins that are known to be involved in the diverse cellular signaling pathways. It is predominantly expressed in the T-cells and localized in the center of immunological synapse upon T-cell receptor (TCR) and CD28 signaling. Activation of PKC-θ leads to the activation of various transcription factors in the nuclei of T-cells, e.g. NF-κB, NFAT, c-Jun, c-Fos and AP-1 that further control the proliferation and differentiation of T-cells. Defective T-cell activation in turn leads to the aberrant expression of apoptosis related proteins that cause the poor T-cell survival. Researchers have found that T-cells deficient in PKC-θ exhibit reduced interleukin-2 (IL-2) production. Apart from this role on IL-2 expression, it also plays crucial roles in the proliferation, differentiation and survival of the T-cells, which make it an attractive therapeutic target for a variety of immunological and T-cell mediated diseases. Hence, new molecules capable of modulating the expression or biological activity of PKC-θ are being developed and tested for their potential as novel therapy for several T-cells mediated disease conditions such as multiple sclerosis, rheumatoid arthritis, asthma, inflammatory bowel disease and organ transplantation, etc. In the present review, we tried to integrate the recent discoveries on PKC-θ including its pharmacology and therapeutic potential, along with brief update on its inhibitor molecules.
Export Options
About this article
Cite this article as:
Chand Sukhvir, Mehta Nisha, Singh Bahia Malkeet, Dixit Anshuman and Silakari Om, Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651625
DOI https://dx.doi.org/10.2174/138161212802651625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Matrix Metalloproteinases in Chronic Pulmonary Diseases: Relevance of the Airway Epithelium
Current Respiratory Medicine Reviews Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
Recent Patents on Anti-Infective Drug Discovery Novel Therapeutic Strategies for Fibrotic Lung Disease: A Review with a Focus on Epithelial-Mesenchymal Transition
Recent Patents on Inflammation & Allergy Drug Discovery Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Mast Cells: Pivotal Players in Cardiovascular Diseases
Current Cardiology Reviews Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Current Drug Targets Exhaled Breath Condensate in Asthma: From Bench to Bedside
Current Medicinal Chemistry Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Role of Chemical Reactivity and Transition State Modeling for Virtual Screening
Combinatorial Chemistry & High Throughput Screening Allergoids for Allergy Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Future Targets for Immune Therapy in Colitis?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Current Drug Safety Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Substance P in Rheumatic Diseases
Current Rheumatology Reviews Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism